[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2017

December 2017 | 115 pages | ID: B8803A18778EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2017

SUMMARY

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 38 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6, 15 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System, Metabolic Disorders, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Ophthalmology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Breast Cancer, Multiple Myeloma (Kahler Disease), Diffuse Large B-Cell Lymphoma, Myelodysplastic Syndrome, Ovarian Cancer, Refractory Acute Myeloid Leukemia, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Atherosclerosis, Colorectal Cancer, Follicular Lymphoma, Hematological Tumor, Inflammation, Lung Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Small-Cell Lung Cancer, Adenocarcinoma, Advanced Malignancy, Alzheimer's Disease, Atopic Dermatitis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Fabry Disease, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypercholesterolemia, Idiopathic Pulmonary Fibrosis, Leukemias, Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Liver Cancer, Myelofibrosis, Myeloproliferative Disorders, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Pre-Diabetes/Impaired Glucose Tolerance, Prostate Cancer, Psoriasis, Renal Cell Carcinoma, Retinal Degeneration, Substance (Drug) Abuse, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) and Uveal Melanoma.

Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
  • The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development
Aptose Biosciences Inc
AstraZeneca Plc
Checkpoint Therapeutics Inc
ConverGene LLC
Dybly AG
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
GlaxoSmithKline Plc
Kainos Medicine Inc
Mitsubishi Tanabe Pharma Corp
Nuevolution AB
Plexxikon Inc
Red Glead Discovery AB
Resverlogix Corp
Trillium Therapeutics Inc
Zenith Epigenetics Ltd
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles
apabetalone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APL-581 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-5153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
birabresib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-223 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-0610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dBET-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCBD-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DYB-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-11313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FT-1101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-525762 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KM-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-2014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS-417 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MZ-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-2734 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-7770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-2853 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-51107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6146 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-1301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2535 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit BRD4 for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Bromodomain Containing Protein-4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTI-281 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZBC-260 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2017: Natures Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1
Nov 27, 2017: Nuevolution to Present New Data on its BET BD1 Program Supporting Effect in Psoriasis/Atopic Dermatitis
Nov 02, 2017: Resverlogix Announces Participation in Upcoming Conferences
Nov 01, 2017: Resverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Oct 27, 2017: Nuevolution to present new data on its BET BD1 program supporting the understanding of the biological mode-of-action
Sep 25, 2017: SignalRx Presents in silico Design of Dual PI3K/BRD4 Inhibitors for Combinatorial Activation of Anti-tumor Immunity in Treating Cancer
Aug 29, 2017: Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix Ongoing BETonMACE Trial
Aug 24, 2017: Cancer Drug Can Reactivate HIV
Jul 25, 2017: Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
Jul 10, 2017: Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
Jul 05, 2017: Trillium Provides Update on Preclinical Development Program, TTI-281
Jun 28, 2017: Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Jun 19, 2017: Nuevolution Presents Additional Positive Animal Results in Lupus From its BET Selective Program
Jun 05, 2017: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1)
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Aptose Biosciences Inc, H2 2017
Pipeline by AstraZeneca Plc, H2 2017
Pipeline by Checkpoint Therapeutics Inc, H2 2017
Pipeline by ConverGene LLC, H2 2017
Pipeline by Dybly AG, H2 2017
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Pipeline by Forma Therapeutics Inc, H2 2017
Pipeline by GlaxoSmithKline Plc, H2 2017
Pipeline by Kainos Medicine Inc, H2 2017
Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Pipeline by Nuevolution AB, H2 2017
Pipeline by Plexxikon Inc, H2 2017
Pipeline by Red Glead Discovery AB, H2 2017
Pipeline by Resverlogix Corp, H2 2017
Pipeline by Trillium Therapeutics Inc, H2 2017
Pipeline by Zenith Epigenetics Ltd, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017

COMPANIES MENTIONED

Aptose Biosciences Inc
AstraZeneca Plc
Checkpoint Therapeutics Inc
ConverGene LLC
Dybly AG
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
GlaxoSmithKline Plc
Kainos Medicine Inc
Mitsubishi Tanabe Pharma Corp
Nuevolution AB
Plexxikon Inc
Red Glead Discovery AB
Resverlogix Corp
Trillium Therapeutics Inc
Zenith Epigenetics Ltd


More Publications